WallStSmart

Abbott Laboratories (ABT)vsAvanos Medical Inc (AVNS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 6205% more annual revenue ($45.13B vs $715.90M). ABT leads profitability with a 13.9% profit margin vs -10.4%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

AVNS

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 3.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: 1.24
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued

Intrinsic value data unavailable for AVNS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

AVNS2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

AVNS4 concerns · Avg: 2.3/10
Market CapQuality
$1.17B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-8.9%2/10

ROE of -8.9% — below average capital efficiency

EPS GrowthGrowth
-21.7%2/10

Earnings declined 21.7%

Free Cash FlowQuality
$-16.60M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : AVNS

The strongest argument for AVNS centers on Price/Book, Debt/Equity.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : AVNS

The primary concerns for AVNS are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ABT profiles as a value stock while AVNS is a turnaround play — different risk/reward profiles.

AVNS carries more volatility with a beta of 1.59 — expect wider price swings.

AVNS is growing revenue faster at 8.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Avanos Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Avanos Medical, Inc. is a medical technology company focused on providing medical device solutions to improve the quality of life for patients in North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. The company is headquartered in Alpharetta, Georgia.

Want to dig deeper into these stocks?